Previous 10 | Next 10 |
Start Time: 09:00 End Time: 10:01 CureVac N.V. (CVAC) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - CFO Ulrike Gnad-Vogt - Interim Chief Development Officer Ronald Plasterk...
Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 Strengthening oncology position based on preparations f...
CureVac BV ( NASDAQ: CVAC ) is scheduled to announce Q3 earnings results on Wednesday, November 16th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $19.77M Over the last 3 months, EPS estimates have seen 1 upward revis...
On Friday, German biotech CureVac N.V. ( NASDAQ: CVAC ) announced preliminary data from its Phase 1 study for CV8102, a messenger-RNA-based cancer vaccine undergoing studies as a single agent and in combination with PD1-antibodies. The company said that the data readout gene...
Data confirm CV8102's safety and ability to strongly mobilize the immune system against tumors Final data of complete Phase 1 dose-escalation and expansion study expected in H1 2023 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 11, 2022 / CureVac N.V. (Nasdaq:CVAC...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for th...
German biotech BioNTech ( NASDAQ: BNTX ) and U.S. partner Pfizer ( NYSE: PFE ) have filed proceedings in a high court in England seeking judgement that their blockbuster mRNA-technology based COVID-19 vaccine does not infringe on two of CureVac's ( NASDAQ: CVAC ...
CureVac BV press release ( NASDAQ: CVAC ): Q2 Pre-tax loss of €57.6M Revenue of €20.1M (-10.3% Y/Y). Cash position of €573.6 million as of June 30, 2022; decreasing headwind of wind-down costs for first-generation COVID-19 vaccine program ...
CureVac ( NASDAQ: CVAC ) said it started a phase 1 trial of a modified COVID-19 mRNA vaccine CV0501, given as a booster dose to previous COVID-19 vaccination. The company added that CV0501, which is being developed in collaboration with GSK ( NYSE: GSK ), is base...
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studies Phase 1 initiated for modified COVID-19 vaccine candidate CV0501, targeting Omi...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...